BioAge Labs (NASDAQ:BIOA) Downgraded to Sell Rating by Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

Other research analysts have also issued reports about the stock. Citigroup upped their target price on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Stock Down 0.5%

BIOA stock opened at $18.81 on Monday. The stock has a 50-day simple moving average of $13.43 and a two-hundred day simple moving average of $8.23. The firm has a market capitalization of $674.34 million, a PE ratio of -12.38 and a beta of 1.38. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $24.00.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million during the quarter.

Insider Buying and Selling at BioAge Labs

In other news, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the sale, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. This represents a 54.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kristen Fortney sold 233,107 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the sale, the chief executive officer owned 976,949 shares of the company’s stock, valued at approximately $17,702,315.88. This represents a 19.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 347,004 shares of company stock worth $5,673,859. 20.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BIOA. Russell Investments Group Ltd. purchased a new stake in BioAge Labs in the 3rd quarter worth $27,000. Police & Firemen s Retirement System of New Jersey bought a new stake in BioAge Labs in the 2nd quarter valued at $27,000. Nisa Investment Advisors LLC increased its holdings in BioAge Labs by 4,219.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after acquiring an additional 10,000 shares during the last quarter. Bank of America Corp DE lifted its stake in BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after purchasing an additional 3,517 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after buying an additional 5,976 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.